Skip to main content

Table 6 Univariable and multivariable survival analysis for OS using Cox proportional hazards models

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Group Immune Biomarker Univariable Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Cohort A ALCs
> = 800
< 800
10.15 (2.46, 41.76) 0.001 7.59 (1.33, 43.16) 0.022
CD4 plus CD8 counts
> = 500
< 500
2.90 (0.95, 8.84) 0.061
PD-L1 IHC
> = 50%
< 50%
2.54 (0.56, 11.45) 0.226
TMB
> = 10
< 10
0.42 (0.05, 3.51) 0.423
Cohort B ALCs
> = 800
< 800
2.38 (0.89, 6.35) 0.084
CD4 plus CD8 counts
> = 500
< 500
3.03 (1.12, 8.20) 0.029 5.96 (1.60, 22.20) 0.008
PD-L1 IHC
> = 50%
< 50%
3.18 (0.97, 10.45) 0.056
TMB
> = 10
< 10
2.18 (0.71, 6.75) 0.175